Preprint · OA
via OpenAlex
adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors
AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · 2013
Abstract
Because of its aberrant activation, the PI3K/AKT/mTOR(definition) signaling pathway represents a pharmacological target in blast cells from patients with acute myelogenous leukemia (AML). Using Reverse Phase Protein Microarrays (RPMA), we have analyzed 20 phosphorylated epitopes of the PI3K/Akt/mTor signal pathway of peripheral blood and bone marrow specimens of 84 patients with newly diagnosed AML. Fresh blast cells were grown for 2 h, 4 h or 20 h untreated or treated with a panel of phase I or phase II Akt allosteric inhibitors, either alone or in combination with the mTOR kinase inhibitor Torin1 or the broad RTK inhibitor Sunitinib. By unsupervised hierarchical clustering a strong phosphorylation/activity of most of the sampled members of the PI3K/Akt/mTOR pathway was observed in 70% of samples from AML patients. Remarkably, however, we observed that inhibition of Akt phosphorylation, as well as of its substrates, was transient, and recovered or even increased far above basal level after 20 h in 60% samples. We demonstrated that inhibition of Akt induces FOXO-dependent insulin receptor expression and IRS-1 activation, attenuating the effect of drug treatment by reactivation of PI3K/Akt. Consistent with this model we found that combined inhibition of Akt and RTKs is much more effective than either alone, revealing the adaptive capabilities of signaling networks in blast cells and highliting the limations of these drugs if used as monotherapy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.6092/unibo/amsdottorato/5155
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Bertacchini, J. (2013). adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors. <em>AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)</em>. https://doi.org/10.6092/unibo/amsdottorato/5155
Vancouver
Bertacchini J. adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors. AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna). 2013. doi:10.6092/unibo/amsdottorato/5155.
BibTeX
@unpublished{jessika2013adapti,
title = {adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors},
author = {Jessika Bertacchini},
journal = {AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)},
year = {2013},
doi = {10.6092/unibo/amsdottorato/5155},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Oncotarget 2010
Open access · OA
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
American Journal of Transplantation 2011
Open access · CC-BY
Rapamycin-Induced Hypophosphatemia and Insulin Resistance Are Associated With mTORC2 Activation and Klotho Expression
Haematologica 2011
Open access · OA
The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells
European Journal of Immunology 2025
Open access · OA
mTOR Modulates NLRP3 Inflammasome Activation via Nuclear Translocation and STAT1 Inhibition
Oxidative Medicine and Cellular Longevity 2021
Open access · CC-BY
Artemisinin Inhibits the Migration and Invasion in Uveal Melanoma via Inhibition of the PI3K/AKT/mTOR Signaling Pathway
Bone 2026
Citation only